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ABSTRACT
Background. Cytoreductive surgery (CRS) with hyper-
thermic intraperitoneal chemotherapy (HIPEC) is a
potentially curative treatment for peritoneal
carcinomatosis.
Objective. The aim of this study was to determine the
predictive value of postoperative inflammatory biomarkers
in assessing complications after CRS and HIPEC.
Methods. A prospective database of 181 patients, who
underwent CRS-HIPEC between March 2014 through
April 2018 in the Erasmus MC, was retrospectively ana-
lyzed. Postoperative complications were defined according
to the serious adverse event (SAE) grading system. Levels
of C-reactive protein (CRP) and white blood cell (WBC)
count were compared between patients with SAE grade
\ 3 and SAE grade C 3. The area under the receiver
operating characteristic curve (AUC) was calculated for
CRP and WBC against SAE C 3 and various intra-ab-
dominal complications.
Results. SAE C 3 postoperative complications occurred
in 50 patients. From the second until the fifth postoperative
day (POD), CRP levels were significantly higher
(p = 0.023, p\ 0.001, p = 0.002, and p = 0.002, respec-
tively) in these patients. CRP concentrations above
166 mg/L on POD3 (AUC 0.75) and 116 mg/L on POD4
(AUC 0.70) were associated with the highest risk of an
SAE C 3. Postoperative WBC levels were not significantly
different between patients with SAE\ 3 and SAE C 3
complications.
Conclusion. Data from our hospital suggest that CRP
levels that continue to rise after POD2 or that are
C 166 mg/L at POD3 or C 116 mg/L at POD4, indicate a
considerable risk for developing high-grade SAEs. The cut-
off values we found can potentially be used as a threshold
for additional diagnostic interventions, after they have been
validated in external data.
Cytoreductive surgery combined with intraoperative
hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
has been considered a potentially curative therapeutic
modality for patients presenting with peritoneal carcino-
matosis (PC).1–3 This extensive surgical treatment has been
associated with improved survival outcomes for selected
patients with PC from colorectal cancer (CRC) and pseu-
domyxoma peritonei (PMP), with 5-year survival rates of
approximately 30% and 74% for CRC and PMP, respec-
tively.4–6 However, it has also been associated with
considerable postoperative morbidity and mortality, with
estimates of approximately 30% and 2–3%, respec-
tively.7–9 When attempting to reduce postoperative
morbidity and mortality, early recognition of high-grade
serious adverse events (SAEs) could be of great
significance.
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C-reactive protein (CRP) is an acute-phase inflammation
protein secreted primarily by liver hepatocytes, smooth
muscle cells, and adipocytes, among others.10 With its half-
life being only 19 h and its increase being proportional to
the degree of the inflammation process, CRP has estab-
lished itself as an inexpensive, highly sensitive but non-
specific biomarker of systemic inflammatory response,11,12
and has been identified as a potential predictive marker of
postoperative complications after abdominal surgery.13,14
Intra-abdominal complications, mainly septic complica-
tions or anastomotic leakage, are associated with mortality,
reoperation, increased hospital stay, and higher costs.15
Research on the utility and predictive value of
biomarkers, such as CRP and WBC (white blood cell)
levels, after CRS and HIPEC has been limited.16 The aim
of this cross-sectional retrospective study was to determine
the predictive value of postoperative CRP and WBC levels
in identifying complications after CRS and HIPEC in
patients with PC from CRC or PMP.
METHODS
Study Population
All patients with PC from CRC or PMP who underwent
CRS-HIPEC in the Erasmus Medical Center between
March 2014 through April 2018 were included in this
study. A prospective database was built based on patients’
chart review by using the electronic medical record system
at this institution. Patients with recurrent peritoneal disease
who underwent a second CRS-HIPEC procedure in the
aforementioned time interval, were also included.
Perioperative Course
CRS-HIPEC procedures were performed by a special-
ized surgical team and in accordance with Dutch CRS and
HIPEC protocols.17 After abdominal access via laparo-
tomy, a thorough assessment of the extent of peritoneal
disease (only in cases with PC from colorectal and
appendiceal cancer) was conducted to determine the Peri-
toneal Cancer Index (PCI) score according to Jacquet and
Sugarbaker.18 If the PCI score was under 20 and/or the
specialized surgeons deemed the peritoneal disease
resectable, the greater omentum, primary tumor (if still
present), affected visceral abdominal organs, affected
parietal surfaces, and all peritoneal implants were resected.
Administration of HIPEC was by way of the open (coli-
seum) technique in which the abdominal cavity was filled
with an iso-osmotic glucose/electrolyte dialysis (Dianeal)
carrier solution, with either mitomycin-C or oxaliplatin
being added to the perfusate as chemotherapeutic agent,
once the desired abdominal temperature of [ 40 C was
reached. After the HIPEC perfusion, intestinal bowel
anastomoses and/or a stomy procedure was performed if
necessary.
Postoperatively, patients were treated following stan-
dard of care for CRS-HIPEC procedures. Laboratory tests
and diagnostic imaging modalities, such as computed
tomography (CT) scans, were liberally used when deemed
necessary. Postoperative complications were retrospec-
tively classified according to the SAE grading system:
SAE = 1 denotes an asymptomatic or mild complication
(intervention not indicated); SAE = 2 denotes a moderate
complication (local or non-invasive intervention indi-
cated); SAE = 3 denotes a severe complication (significant
but not immediately life-threatening, radiological or sur-
gical intervention indicated); SAE = 4 denotes a life-
threatening complication (reoperation and/or prolonged
intensive care unit [ICU] stay indicated); and SAE = 5
denotes in-hospital death related to the adverse event.17,19
Intra-abdominal gastrointestinal complications included
anastomotic leakage, bowel perforation or ischemia/
necrosis. The postoperative period was defined as the
duration of the entire hospital stay following CRS and
HIPEC, regardless of length.
Laboratory Data
Laboratory results (including postoperative biomarkers)
of all patients who underwent CRS-HIPEC were recorded
on arrival to the ICU and then daily during the patient’s
usually brief stay (1–3 days). When transferred to the ward,
CRP levels were drawn in addition to a complete blood
count (CBC), including white blood cell (WBC) count and
blood chemistry in patients, usually three times a week
(according to the Erasmus MC CRS-HIPEC protocol). CRP
and WBC levels were routinely measured on postoperative
days (PODs) 1, 2, 3, 4, and/or 5. Laboratory data were
gathered retrospectively.
Statistical Analysis
Quantitative variables are presented as median with
interquartile range (IQR), while categorical variables are
presented as counts with percentages. Daily postoperative
CRP values and WBC count between the SAE\ 3 and
SAE C 3 groups were compared using the Mann–Whitney
U-test (non-parametric). All tests were performed two-
sided and results were considered significantly different
when the p value was\ 0.05. Diagnostic accuracy of CRP
and WBC values on consecutive PODs was analyzed using
the receiver operating characteristic (ROC) curve by cal-
culating separate cut-off levels for CRP and WBC with
optimal sensitivity and specificity. Outcomes assessed were
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intra-abdominal gastrointestinal complications, intra-ab-
dominal abscess, and SAE C 3. Areas under the receiver
operating characteristic curves (AUCs) were used to
compare ROC curves. Statistical analyses were performed
using the Statistical Package for Social Sciences (SPSS)
version 21.0 (IBM Corporation, Armonk, NY, USA).
Ethical Considerations
All study procedures were performed according to the
Erasmus MC Research Codes and with permission of the




From March 2014 to May 2018, 181 patients underwent
CRS-HIPEC in the Erasmus Medical Center. Patient- and
tumor-related characteristics are described in Table 1.
Three patients underwent a re-HIPEC within the afore-
mentioned time interval, bringing the total number of
analyzed CRS-HIPEC procedures to 184. Primary tumors
included 147 colorectal adenocarcinomas (81.2%), 22
PMPs (12.2%), and 12 appendiceal adenocarcinomas
(6.6%). Comparison of the baseline characteristics showed
that the SAE C 3 group comprised significantly more male
patients (67% vs. 44%; p = 0.006). No further differences
at baseline existed between groups.
Intraoperative and Postoperative Course
Table 2 reports the intraoperative course characteristics.
Median procedure time of CRS-HIPEC was 398 min
[327–475]. Of all patients with peritoneally disseminated
CRC (n = 147), the median PCI was 10.6–16 Bowel anas-
tomosis was performed in 109 procedures (59.2%), and
median blood loss was 1183 mL [714–2075]. In the
SAE C 3 group, significantly more cholecystectomies
were performed (16% vs. 3.7%; p = 0.004). In addition,
median intraoperative blood loss was significantly more in
the SAE C 3 group (1533 mL [900–2700] vs. 1063 mL
[688–1763]; p = 0.005). SAE score C 3 complications
occurred after 50 (27.2%) procedures (Table 3), of which
36% were gastrointestinal complications (anastomotic
leakage and bowel perforation/ischemia). The most fre-
quently occurring major complications in the cohort were
intra-abdominal abscess (11.4%), anastomotic leakage
(4.9%), intra-abdominal bleeding (3.8%), and pulmonary
embolisms (3.8%). Reoperation had to be performed in 28
(15.2%) patients. Median duration of hospital stay was
17 days.13–23
Postoperative Biomarkers
The overall evolution of median CRP values up to POD
5 is shown in Fig. 1a. Overall, the median CRP value
increased from 89.5 mg/L [67.3–126] (POD 1) to a peak of
136 mg/L [95–206] (POD 2), and then decreased to
113 mg/L [64–185] (POD 3). The proportion of missing
data was 52.7% on POD 4, but surpassed 60% on PODs 5
and 6. In patients who developed an SAE C 3 complica-
tion, the median CRP value increased from 92 mg/L
[65.5–142.5] (POD 1) to 202.5 mg/L [102.3–282] (POD 3),
and ultimately to 182 mg/L [71–276] (POD 5). Six (12%)
SAE C 3 complications were diagnosed and treated by
reoperation before POD 3, thus resulting in a deviated
course of CRP levels on POD 3 and beyond. Of all SAE
C 3 complications, four (8%) were diagnosed and treated
by reoperation between POD 3 and POD 5. In 39 (78%)
patients, SAE C 3 complications were diagnosed after
peak CRP concentration (POD 3), with a median of
8 days5–10 following CRS-HIPEC. As can be seen in
Fig. 1a, in cases of postoperative complications with SAE
grade\ 3, CRP concentrations peaked on POD 2 (127 mg/
L), and also peaked at POD 3 (205 mg/L) in patients with
SAE C 3. Median CRP values were significantly higher
between patients with SAE C 3 versus patients with
SAE\ 3 on POD 2 (173.5 mg/L vs. 127 mg/L;
p = 0.023), POD 3 (202.5 mg/L vs. 104 mg/L; p\ 0.001),
POD 4 (137 mg/L vs. 73.5 mg/L; p = 0.002), and POD 5
(182 mg/L vs. 80.5 mg/L; p = 0.002).
No similar trends were observed for postoperative WBC
levels (Fig. 1b). Overall, median WBC count on POD 1
was 13.4*109/L [10.8–16.2], which declined steadily to
7.9*109/L [5.6–10.7] on POD 5. WBC did not differ sig-
nificantly on the first 5 PODs between patients who
developed SAE grade C 3 complications versus patients
who developed SAE grade\ 3 complications. However, in
18 patients who developed either anastomotic leakage,
bowel ischemia, or perforation, median WBC levels first
declined, from 14.7*109/L [11.3–17.8] at POD 1 to
11.0*109/L [9.8–12.9] on POD 3, after which they rose to
12.6*109/L [8.2–16.6] on POD 4 (p = 0.031).
Predictive Value of Biomarkers
Figure 2a, b shows the ROC curves for SAE C 3 against
CRP values on PODs 3 (AUC 0.75, 95% confidence
interval [CI] 0.65–0.85; p\ 0.001) and 4 (AUC 0.70, 95%
CI 0.59–0.81; p = 0.002), respectively. On POD 3, a cut-
off CRP value of 166 mg/L had a sensitivity of 61.1% and
a specificity of 84.5%. On POD 4, sensitivity and
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specificity were 54.8% and 76.8%, respectively, for a cut-
off CRP value of 116 mg/L. AUCs for the ROC curves for
gastrointestinal complications (either anastomotic leakage,
bowel ischemia/necrosis, or perforation) against CRP val-
ues on PODs 3 and 4 were 0.71 (95% CI 0.54–0.87;
p = 0.01) and 0.76 (95% CI 0.58–0.93; p = 0.01) respec-
tively (Fig. 2c, d). The cut-off CRP value at POD 3 was
188 mg/L, with a sensitivity of 61.5% and specificity of
81.7% (Fig. 2c). At POD 4, CRP C 160.5 mg/L had a
sensitivity for a gastrointestinal complication of 66.7% and
a specificity of 82.1%. We also examined whether the CRP
levels on PODs 3 and 4 can predict an intra-abdominal
abscess (Figs. 2e, f). The AUCs for the ROC curves for
CRP values on PODs 3 and 4 were 0.75 (95% CI
0.60–0.90; p = 0.002) and 0.61 (95% CI 0.44–0.79;
p = 0.179), respectively. The cut-off CRP level on POD 3
was 166 mg/L, with a sensitivity of 71.4% and specificity
of 77.6%.
Figure 3 demonstrates poor diagnostic accuracy of
postoperative WBC levels on POD 3 (AUC 0.56, 95% CI
0.45–0.68; p = 0.25) and POD 4 (AUC 0.60, 95% CI
0.47–0.73; p = 0.14) in detecting patients with SAE
grade C 3 complications (Figs. 3a, b) and intra-abdominal
abscesses (Figs. 3e, f). In contrast, the discriminative
properties of postoperative WBC levels on POD 4 (AUC
0.71, 95% CI 0.54–0.88, p = 0.031) for detecting gas-
trointestinal complications (either anastomotic leakage,
bowel ischemia/necrosis, or perforation) were greater
(Figs. 3c, d). In addition, a cut-off WBC level of 11.9*109/
L was determined, with a sensitivity and specificity of 60%
and 82.1%, respectively.
DISCUSSION
The aim of this retrospective study was to determine the
value of early postoperative inflammatory biomarker levels
in identifying patients at risk of developing high-grade
SAEs (SAE grade C 3) following CRS-HIPEC. To our
knowledge, this is the first study to consider postoperative
CRP and WBC levels as a diagnostic tool for identifying
high-grade complications following CRS-HIPEC in
patients with CRC, appendiceal cancer, and PMP. In cases
of SAE grade\ 3 complications, CRP concentrations










Female 91 (50.3) 75 (56.4) 16 (33.3) 0.006
Age, years 62 [53–69] 60 [52–70] 64 [56.3–68.8] NS
BMI 25.6 [22.8–29] 25.4 [22.3–28.7] 26.4 [24.1–29.4] NS
Smoking (past or current) 88 (48.6) 60 (45.1) 28 (58.3) NS
Diabetes 21 (11.6) 14 (10.5) 7 (14.6) NS
IDDM 8 (38) 6 (42.9) 2 (28.6) NS
Hypertension 42 (23.2) 29 (21.8) 13 (27.1) NS
ASA classification NS
1 34 (18.8) 28 (21.1) 6 (12.5)
2 115 (63.5) 84 (63.2) 31 (64.6)
3 32 (17.7) 21 (15.8) 11 (22.9)
Primary tumor NS
Appendix cancer 12 (6.6) 8 (6) 4 (8.3)
PMP 22 (12.2) 15 (11.3) 7 (14.6)
CRC ascending colon 60 (33.1) 47 (35.3) 13 (27.1)
CRC transverse colon 10 (5.5) 7 (5.3) 3 (6.3)
CRC descending colon 16 (8.8) 12 (9.0) 4 (8.3)
CRC sigmoid 39 (21.5) 29 (21.8) 10 (20.8)
CRC rectum 22 (12.2) 15 (11.3) 7 (14.6)
PC diagnosis NS
Synchronous 88 (48.6) 65 (48.9) 23 (47.9)
Metachronous 93 (51.4) 68 (51.1) 25 (52.1)
Continuous variables are reported as median [IQR], and proportions are reported as n (%)
SAE serious adverse event, BMI body mass index, IDDM insulin-dependent diabetes mellitus, ASA America
Society of Anesthesiologists, PMP pseudomyxoma peritonei, PC peritoneal carcinomatosis, IQR
interquartile range, NS non-significant, CRC colorectal cancer
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PCIa 10 [6–16] 10 [5–16] 14 [8–16] NS
(Partially) resected organs
Omentum 174 (94.6) 128 (95.5) 46 (94) NS
Spleen 12 (6.5) 6 (4.5) 6 (12) NS
Urether 5 (2.7) 3 (2.2) 2 (4) NS
Bladder 4 (2.2) 4 (3) 0 NS
Uterusb 36 (39.6) 28 (20.9) 8 (16) NS
Ovariesb 63 (69.2) 48 (35.8) 14 (28) NS
Stomach 2 (1.1) 1 (0.7) 1 (2) NS
Liver 10 (5.4) 7 (5.2) 3 (6) NS
Pancreas 11(6) 7 (5.2) 4 (8) NS
Gallbladder 12 (6.5) 4 (3) 8 (16) 0.004
Duodenum 10 (5.4) 4 (3) 1 (2) NS
Small intestine 52 (28.3) 35 (26.1) 17 (34) NS
Appendix 10 (5.4) 7 (5.2) 3 (6) NS
Ileocecal 22 (12) 13 (9.7) 9 (18) NS
Ascending colon 40 (21.7) 27 (20.1) 13 (26) NS
Transverse colon 21 (11.4) 12 (9) 9 (18) NS
Descending colon 12 (6.5) 9 (6.7) 3 (6) NS
Sigmoid colon 55 (29.9) 39 (29.1) 16 (32) NS
Rectum 47 (25.5) 32 (23.9) 15 (30) NS
Diaphragm
Left 20 (10.9) 14 (10.4) 6 (12) NS
Right 42 (22.8) 27 (20.1) 15 (30) NS
Peritoneum
Left 59 (32.1) 43 (32.1) 16 (32) NS
Right 73 (39.7) 52 (38.8) 21 (42) NS
Pelvic 71 (38.6) 57 (42.5) 14 (28) NS
CCR score NS
R1 177 (96.2) 130 (97) 47 (94)
R2a 5 (2.7) 3 (2.2) 2 (4)
R2b 2 (1.1) 2 (1.5) 0
Number of bowel anastomoses NS
0 75 (40.8) 60 (44.8) 15 (30)
1 86 (46.7) 62 (46.3) 24 (48)
2 17 (9.2) 8 (6) 9 (18)
3 4 (2.2) 2 (1.5) 2 (4)
4 2 (1.1) 2 (1.5) 0
Stomy NS
Ileostomy 11 (6) 7 (5.2) 4 (8)
Colostomy 61 (33.2) 44 (32.8) 17 (34)
Double barrel colostomy 2 (1.1) 2 (1.5) 0
HIPEC regimen NS
Mitomycin-C 164 (89.1) 121 (90.3) 43 (86)
Oxaliplatin (5-fluorouracil, leucovorin) 11 (6) 9 (6.7) 2 (4)
Other 9 (4.9) 5 (3.7) 4 (8)
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SAE C 3 complications. The differences in CRP concen-
trations were significant from POD 2 until POD 5 between
the aforementioned two groups. Most (78%) postoperative
SAE C 3 complications were diagnosed after peak CRP
concentrations.
In this study, POD 3 and POD 4 were chosen as the time
points for calculating AUCs, considering the compelling
research20 that suggests that postoperative CRP reaches a
peak at POD 3 or 4, with better predictive accuracy than
CRP on PODs 1 or 2. CRP values on POD 3 had moderate
diagnostic accuracy (AUCs[ 0.70) for predicting SAE
C 3, with cut-off values of 166 mg/L on POD 3 (sensitivity
61.1%; specificity 84.5%). Gans et al.20 reported a similar
CRP cut-off value of 159 mg/L on POD 3 (sensitivity 77%;
specificity 77%) in a meta-analysis regarding ‘major
abdominal surgery’. The data observed in our tertiary
center suggest that high CRP levels on PODs 3 and 4









Blood loss, mL 1183 [714–2075] 1063 [688–1763] 1533 [900–2700] 0.005
Procedure time, min 398 [327–475] 396 [326–454] 399 [325–515] NS
Continuous variables are reported as median [IQR], and proportions are reported as n (%)
SAE serious adverse event, PCI Peritoneal Cancer Index, CCR completeness of cytoreduction, IQR interquartile range, NS non-significant, CRS-
HIPEC cytoreductive surgery-hyperthermic intraperitoneal chemotherapy
aApplicable to CRS-HIPEC procedures for colorectal cancer (n = 147)










Intra-abdominal bleeding 7 (3.8) 1 (0.7) 6 (12)
Anastomotic leakagea 9 (4.9) 0 9 (18)
Bowel perforation/ischemia 9 (4.9) 0 9 (18)
Wound dehiscence 5 (2.7) 1 (0.7) 4 (8)
Intra-abdominal abscess 21 (11.4) 3 (2.2) 18 (36)
Wound infection 20 (10.9) 15 (11.2) 5 (10)
UTI 16 (8.7) 14 (10.4) 2 (4)
Pneumonia 8 (4.3) 6 (4.5) 2 (4)
Pulmonary embolism 7 (3.8) 2 (1.5) 5 (10)







Reoperation 28 (15.2) 0 28 (56)
ICU stay 3 [2–3] 3 [2–3] 4 [3–8]
Hospital stay 17 [13–23] 15.5 [12–18.3] 30 [19–39]
In-hospital mortality 6 (3.3) 0 6 (12)
Continuous variables are reported as median [IQR], and proportions are reported as n (%)
SAE serious adverse event, UTI urinary tract infection, ICU intensive care unit, IQR interquartile range,
CRS-HIPEC cytoreductive surgery-hyperthermic intraperitoneal chemotherapy
aProportion of all patients with bowel anastomosis after CRS-HIPEC (n = 109)
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SAEs (i.e. SAE grade C 3). In addition, considering the
peak in CRP levels at POD 2 in patients not developing
high-grade SAEs versus the peak at POD 3 in patients who
do develop high-grade SAEs, clinicians should be extra
cautious if CRP levels keep rising after POD 2, especially
when they exceed the aforementioned cut-off levels at
PODs 3 and 4. These cut-off CRP values may potentially
be set as thresholds for additional (abdominal) imaging.
External validation should be performed before incorpo-
rating this in routine clinical practice.
These aforementioned results suggest that CRP might be
utilized to identify patients who are at high risk of devel-
oping postoperative SAE C 3 complications. In clinical
practice, besides CRP, other variables such as heart rate,
temperature, blood pressure, and urinary output are taken
into account in decision making for further diagnostics or a
reoperation. Taking the inexpensiveness of the labora-
tory test into account (less than €4 in The Netherlands),
also makes this biomarker even more attractive for post-
operative monitoring. The current study exclusively
analyzed CRP levels and did not consider other clinical
parameters. These clinical parameters can influence the
pretest probability of developing high-grade SAEs, thereby
improving the predictive value of CRP. Hence, if CRP
levels are C 166 at POD 3, clinicians might pay better
attention to other clinical parameters. Consequently, the
early detection rate of high-grade SAEs might increase.
Unfortunately, it was not possible to predict specific
complications based on CRP levels alone. Although CRP
levels were significantly increased in patients who devel-
oped intra-abdominal abscesses or gastrointestinal leakage,
the predictive value of CRP for these specific complica-
tions was low. This can be explained first by the fact that
CRP is a non-specific biomarker and therefore the predic-
tive ability for specific complications is low. Second, the
number of events per complication was too small for
conclusive statistical analysis; thus, elevated CRP can
increase caution for the high possibility that serious com-
plications are evolving, but it cannot precisely predict what
complication will develop.
POD1 POD2 POD3 POD4 POD5



















SAE < 3 (N=134)
SAE > 3 (N=50)
Anastomotic leakage/ bowel ischemia or perforation (N=18)
Intra-abdominal abscess (N=21)
All procedures (N=184)
SAE < 3 (N=134)
SAE > 3 (N=50)



















FIG. 1 a Postoperative CRP
values after CRS and HIPEC.
b Postoperative WBC count
after CRS and HIPEC. POD
postoperative day, CRP
C-reactive protein, SAE serious
adverse event, WBC white blood
cell count
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WBC count did not differ significantly between the
SAE\ 3 and SAE C 3 groups; however, a significant
increase in WBC levels from POD 3 to POD 4 was
observed in patients with gastrointestinal complications,
with a corresponding ROC curve demonstrating moderate
diagnostic accuracy. Nonetheless, WBC appears to be less
useful, in general, than CRP for detecting high-grade
SAEs. A possible explanation might be the low WBC
levels due to extensive blood loss and dilution from





















































































AUC=0.746, p<0.001 AUC=0.700, p<0.002
AUC=0.708, p<0.014 AUC=0.757, p<0.012




FIG. 2 a–f Receiver operating
characteristic curve for
C-reactive protein. SAE C 3 at
a POD 3 and b POD4;
gastrointestinal complications at
c POD 3 and d POD 4; intra-
abdominal abscess at e POD 3
and f POD 4. AUC area under
the receiver operating
characteristic curve, SAE
serious adverse event, POD
postoperative day
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have also shown suppression of the cellular immune
response after major surgery, trauma, or injury.21,22 For
CRS-HIPEC procedures specifically, mild leukopenia has
been reported as a result of systemic uptake of intraperi-
toneal chemotherapy.23,24 These reasons might explain
why WBC does not seem to be a reliable predictor of early
postoperative complications in patients undergoing CRS-
HIPEC. This observation has been previously reported for
colorectal surgery.25
The current study found significant differences between
the SAE\ 3 and SAE C 3 groups in relation to sex,





















































































AUC=0.564, p=0.253 AUC=0.596, p=0.136
AUC=0.606, p=0.211 AUC=0.711, p=0.031




FIG. 3 a–f Receiver operating
characteristic curves for white
blood cell count. SAE C 3 at
a POD 3 and b POD 4;
gastrointestinal complications at
c POD 3 and d POD 4; intra-
abdominal abscess at e POD 3
and (f) POD 4. AUC area under
the receiver operating
characteristic curve, SAE
serious adverse event, POD
postoperative day
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published literature, the effect of sex on postoperative
outcomes has been debated. Some earlier studies demon-
strated that male patients have a higher risk of
complications following colorectal surgery (open and
laparoscopic),26 and that higher rates of anastomotic leak-
ages were associated with male sex.27 However, these
aforementioned associations with sex have not been
demonstrated in other (retrospective) cohort studies of
patients undergoing CRS and HIPEC.28–30 In the current
data, no explanation could be found for this observation. In
the SAE C 3 group, significantly more cholecystectomies
were performed during CRS. Cholecystectomy has not
been earlier described as a risk factor for developing high-
grade SAEs after CRS and HIPEC. As most of the chole-
cystectomies were performed in patients with PMPs, it is
very likely that cholecystectomy is an indicator of the
extent of disease spread, and thus the extent of surgery. The
significant difference in the proportion of cholecystec-
tomies between the SAE\ 3 and SAE C 3 groups may be
explained via this underlying mechanism. Lastly, median
blood loss was significantly higher in the SAE C 3 group.
This observation was expected as extensive blood loss has
been associated with postoperative morbidity in both gen-
eral colorectal surgery and the CRS and HIPEC
procedures.26,31,32 Perioperative blood loss may, to some
extent, reflect the extensiveness of the procedure; there will
generally be more blood loss in larger procedures, which
results in an increased risk of developing high-grade
SAEs.28–30
Limitations
There are some limitations to the current study,
including, first, the retrospective nature of data collection
(including laboratory markers) and the limited study sam-
ple size, and, second, the amount of (possibly non-random)
missing laboratory data, particularly on POD 4. This is
explained by the postoperative HIPEC protocol in the
Erasmus MC, which states that laboratory testing should be
performed daily on the first, second, and third PODs, and
afterwards three times per week on the ward. Third, only
the ‘early’ (until POD 5) CRP levels were analyzed in this
study, since most CRP values after POD 5 were more likely
to be ‘missing not at random’: missingness related to a
speedy recovery, and thus unnecessary laboratory testing
and/or hospital discharge (‘confounding by indication’).
However, this observation was not considered an issue for
this particular study, considering its aim was to evaluate
CRP as a biomarker for early detection of SAE C 3
complications. In addition, Medina Fernandez et al.16
suggested that CRP cut-off values might only be of value in
the first postoperative week, as their results found CRP
levels in the second postoperative week to be not
significantly different between patients who developed
infectious complications and those who did not, following
CRS-HIPEC for ovarian PC.
CONCLUSION
With a cut-off value of 166 mg/L on POD 3 after CRS-
HIPEC, CRP is a good screening test with high specificity
in differentiating between SAE\ 3 and SAE C 3 com-
plications. Following CRS-HIPEC, postoperative CRP
levels might not only aid in patient selection to prevent
overuse of imaging but also for earlier and safe hospital
discharge. More prospective studies are needed to more
accurately determine the predictive ability of early post-
operative CRP levels, in combination with clinical
parameters, after CRS-HIPEC.
DISCLOSURES Job P. van Kooten, Arvind Oemrawsingh, Nadine
L. de Boer, Cornelis Verhoef, Jacobus W.A. Burger, Eva V.E.
Madsen, and Alexandra R.M. Brandt–Kerkhof have no conflicts of
interest to declare.
OPEN ACCESS This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate
if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons licence and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this licence, visit http://creativecommons.
org/licenses/by/4.0/.
REFERENCES
1. Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment
of peritoneal carcinomatosis from nonovarian origin by cytore-
ductive surgery combined with perioperative intraperitoneal
chemotherapy: a multi-institutional study of 1,290 patients.
Cancer. 2010;116(24):5608–618.
2. Maggiori L, Elias D. Curative treatment of colorectal peritoneal
carcinomatosis: current status and future trends. Eur J Surg
Oncol. 2010;36(7):599–603.
3. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H.
8-year follow-up of randomized trial: cytoreduction and hyper-
thermic intraperitoneal chemotherapy versus systemic
chemotherapy in patients with peritoneal carcinomatosis of col-
orectal cancer. Ann Surg Oncol. 2008;15(9):2426–432.
4. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term
outcome data of patients with pseudomyxoma peritonei from
appendiceal origin treated by a strategy of cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy. J Clin Oncol.
2012;30(20):2449–456.
5. Levine EA, Stewart JH 4th, Shen P, Russell GB, Loggie BL,
Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal
J. P. Kooten et al.
surface malignancy: experience with 1,000 patients. J Am Coll
Surg. 2014;218(4):573–85.
6. Huang CQ, Min Y, Wang SY, et al. Cytoreductive surgery plus
hyperthermic intraperitoneal chemotherapy improves survival for
peritoneal carcinomatosis from colorectal cancer: a systematic
review and meta-analysis of current evidence. Oncotarget.
2017;8(33):55657–5683.
7. Bartlett EK, Meise C, Roses RE, Fraker DL, Kelz RR, Karak-
ousis GC. Morbidity and mortality of cytoreduction with
intraperitoneal chemotherapy: outcomes from the ACS NSQIP
database. Ann Surg Oncol. 2014;21(5):1494–500.
8. Jafari MD, Halabi WJ, Stamos MJ, et al. Surgical outcomes of
hyperthermic intraperitoneal chemotherapy: analysis of the
American College of Surgeons National Surgical Quality
Improvement Program. JAMA Surg. 2014;149(2):170–75.
9. Peters MG, Bartlett EK, Roses RE, Kelz RR, Fraker DL,
Karakousis GC. Age-related morbidity and mortality with
cytoreductive surgery. Ann Surg Oncol. 2015;22 Suppl 3:S898–
S904.
10. Du Clos TW. Function of C-reactive protein. Ann Med.
2000;32(4):274–278.
11. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Criti Care.
2010;14(1):R15.
12. Hoeboer SH, Groeneveld AB, Engels N, van Genderen M,
Wijnhoven BP, van Bommel J. Rising C-reactive protein and
procalcitonin levels precede early complications after
esophagectomy. J Gastrointest Surg. 2015;19(4):613–24.
13. MacKay GJ, Molloy RG, O’Dwyer PJ. C-reactive protein as a
predictor of postoperative infective complications following
elective colorectal resection. Color Dis. 2011;13(5):583-587.
14. Ortega-Deballon P, Radais F, Facy O, et al. C-reactive protein is
an early predictor of septic complications after elective colorectal
surgery. World J Surg. 2010;34(4):808-814.
15. Sparreboom CL, Wu ZQ, Ji JF, Lange JF. Integrated approach to
colorectal anastomotic leakage: communication, infection and
healing disturbances. World J Gastroenterol.
2016;22(32):7226–235.
16. Medina Fernandez FJ, Munoz-Casares FC, Arjona-Sanchez A,
et al. Postoperative time course and utility of inflammatory
markers in patients with ovarian peritoneal carcinomatosis treated
with neoadjuvant chemotherapy, cytoreductive surgery, and
HIPEC. Ann Surg Oncol. 2015;22(4):1332–340.
17. Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and
HIPEC in the Netherlands: nationwide long-term outcome fol-
lowing the Dutch protocol. Annals of surgical oncology.
2013;20(13):4224-4230.
18. Jacquet P, Sugarbaker PH. Clinical research methodologies in
diagnosis and staging of patients with peritoneal carcinomatosis.
Cancer Treat Rese. 1996;82:359-374.
19. Trotti A, Colevas AD, Setser A, et al. CTCAE v30: development
of a comprehensive grading system for the adverse effects of
cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181.
20. Gans SL, Atema JJ, van Dieren S, Groot Koerkamp B, Boer-
meester MA. Diagnostic value of C-reactive protein to rule out
infectious complications after major abdominal surgery: a sys-
tematic review and meta-analysis. Int J Colorectal Dis.
2015;30(7):861-873.
21. Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M.
Immunosuppression following surgical and traumatic injury. Surg
Today. 2010;40(9):793-808.
22. Franke A, Lante W, Kurig E, Zoller LG, Weinhold C, Markewitz
A. Hyporesponsiveness of T cell subsets after cardiac surgery: a
product of altered cell function or merely a result of absolute cell
count changes in peripheral blood? Eur J Cardiothorac Surg.
2006;30(1):64–71.
23. Hakeam HA, Arab A, Azzam A, Alyahya Z, Eldali AM, Amin T.
Incidence of leukopenia and thrombocytopenia with cisplatin plus
mitomycin-c versus melphalan in patients undergoing cytore-
ductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC). Cancer Chemother Pharmacol.
2018;81(4):697–704.
24. Horvath P, Beckert S, Struller F, Konigsrainer A, Konigsrainer I.
Incidence of leukopenia after intraperitoneal vs combined intra-
venous/intraperitoneal chemotherapy in pseudomyxoma
peritonei. World J Gastrointest Pharmacol Ther.
2016;7(3):434–39.
25. Warschkow R, Tarantino I, Torzewski M, Naf F, Lange J, Steffen
T. Diagnostic accuracy of C-reactive protein and white blood cell
counts in the early detection of inflammatory complications after
open resection of colorectal cancer: a retrospective study of 1,187
patients. Int J Colorectal Dis. 2011;26(11):1405–1413.
26. Kirchhoff P, Clavien PA, Hahnloser D. Complications in col-
orectal surgery: risk factors and preventive strategies. Patient Saf
Surg. 2010;4(1):5.
27. Lipska MA, Bissett IP, Parry BR, Merrie AE. Anastomotic
leakage after lower gastrointestinal anastomosis: men are at a
higher risk. ANZ J Surg. 2006;76(7):579–85.
28. Stephens AD, Alderman R, Chang D, et al. Morbidity and mor-
tality analysis of 200 treatments with cytoreductive surgery and
hyperthermic intraoperative intraperitoneal chemotherapy using
the coliseum technique. Ann Surg Oncol. 1999;6(8):790–796.
29. Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE,
Sugarbaker PH. Perioperative outcomes of cytoreductive surgery
and perioperative intraperitoneal chemotherapy for non-appen-
diceal peritoneal carcinomatosis from a prospective database. J
Surg Oncol. 2007;96(2):102–112.
30. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohy-
perthermia using a closed abdominal procedure and cytoreductive
surgery for the treatment of peritoneal carcinomatosis: morbidity
and mortality analysis of 216 consecutive procedures. Ann Surg
Oncol. 2003;10(8):863–69.
31. Mizumoto A, Canbay E, Hirano M, et al. Morbidity and mortality
outcomes of cytoreductive surgery and hyperthermic intraperi-
toneal chemotherapy at a single institution in Japan.
Gastroenterol Res Pract. 2012;2012:836425.
32. Cardi M, Sibio S, Di Marzo F, et al. Prognostic factors influ-
encing infectious complications after cytoreductive surgery and
HIPEC: results from a tertiary referral center. Gastroenterol Res
Pract. 2019;2019:2824073.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Inflammatory Biomarkers Following CRS-HIPEC
